KRT-232: A phase 1b/2 trial of KRT-232 in combination with acalabrutinib in DLBCL or CLL

This phase 1b/2 trial is testing the treatment KRT-232 combined with acalabrutinib in people with diffuse large B-cell lymphoma (DLBCL) or chronic lymphocytic leukaemia (CLL) that has either stopped responding to treatment (refractory) or has returned after treatment (relapsed).

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT04502394
 

Trial aim and background 

The aim of this trial is to find out how safe and effective the medication KRT-232 is in relapsed or refractory DLBCL or CLL when given in combination with acalabrutinib. KRT-232 is an experimental anticancer drug which inhibits an oncogene called MDM2. An oncogene is a gene that can transform a cell into a cancer gene.

In the trial people with DLBCL and CLL will have KRT-232 as an oral tablet once a day for days 1-7 in a 28 day cycle and acalabrutinib daily. The primary aims are to establish the maximum tolerated dose of KRT-232 along with the rate of recovery/remission. 

Part of this trial is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter

Adults aged over 18 with a diagnosis of DLBCL who have had two previous lines of treatment, or with CLL who have had one line of treatment may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • St James’s University Hospital, Leeds
  • Kings College Hospital, London
  • Royal Marsden Foundation Trust, London
  • University Hospital Southampton NHS Foundation Trust, Southampton

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://beta.clinicaltrials.gov/study/NCT04502394

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.